Inhibitory Interaction Between Calcium Channel Blocker and Clopidogrel - Efficacy of Cilostazol to Overcome It
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seung-Pyo | - |
dc.contributor.author | Bae, Jang-Whan | - |
dc.contributor.author | Park, Kyung Woo | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Bae, Jang-Ho | - |
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Cho, Myeong-Chan | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-09-07T06:44:30Z | - |
dc.date.available | 2021-09-07T06:44:30Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2011-11 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111281 | - |
dc.description.abstract | Background: The clinical effect of, and additive measures to overcome the possible inhibitory calcium channel blocker (CCB) - clopidogrel interaction in Asian patients undergoing percutaneous coronary intervention is unknown. Methods and Results: A total of 900 Korean patients enrolled for the multicenter, prospective, randomized Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation (CILON-T) trial were divided into 4 groups depending on CCB prescription and type of anti-platelet therapy (dual [DAT] vs. triple [TAT; addition of cilostazol to DAT]) in a 2x2 factorial manner. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI. On-treatment platelet reactivity (OPR) was assessed on VerifyNow P2Y12 assay. Concomitant CCB use increased OPR in the DAT group (mean +/- SEM: 251.2 +/- 7.6 vs. 225.6 +/- 5.1; P=0.008), but not in the TAT group (214.5 +/- 9.1 vs. 203.4 +/- 5.6; P=0.294). Primary endpoint increased by use of CCB in patients with DAT (4.9% vs. 0.9%, P=0.016), but not in those with TAT (0% vs. 1.8%, P=0.346). Addition of cilostazol to DAT reduced OPR and clinical events in patients taking CCB (P=0.007 for P2Y12 reaction units; P=0.027 for thrombotic events). CCB without concomitant cilostazol use was a significant predictor of total thrombotic events. Conclusions: Concomitant use of CCB may weaken the anti-platelet effect of clopidogrel and increase subsequent thrombotic events in Asian subjects. This hazardous CCB clopidogrel interaction may be overcome by addition of cilostazol. (Circ J 2011; 75: 2581-2589) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | JAPANESE CIRCULATION SOC | - |
dc.subject | ELUTING STENT IMPLANTATION | - |
dc.subject | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject | ISCHEMIC VASCULAR COMPLICATIONS | - |
dc.subject | HUMAN CYTOCHROME-P450 ENZYMES | - |
dc.subject | TRIPLE ANTIPLATELET THERAPY | - |
dc.subject | OF-CARE ASSAY | - |
dc.subject | PLATELET REACTIVITY | - |
dc.subject | MYOCARDIAL-INFARCTION | - |
dc.subject | ACTIVE METABOLITE | - |
dc.subject | CLINICAL-EFFICACY | - |
dc.title | Inhibitory Interaction Between Calcium Channel Blocker and Clopidogrel - Efficacy of Cilostazol to Overcome It | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1253/circj.CJ-11-0113 | - |
dc.identifier.scopusid | 2-s2.0-80054965588 | - |
dc.identifier.wosid | 000296403100014 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, v.75, no.11, pp.2581 - 2589 | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.citation.title | CIRCULATION JOURNAL | - |
dc.citation.volume | 75 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2581 | - |
dc.citation.endPage | 2589 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ELUTING STENT IMPLANTATION | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | ISCHEMIC VASCULAR COMPLICATIONS | - |
dc.subject.keywordPlus | HUMAN CYTOCHROME-P450 ENZYMES | - |
dc.subject.keywordPlus | TRIPLE ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | OF-CARE ASSAY | - |
dc.subject.keywordPlus | PLATELET REACTIVITY | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | ACTIVE METABOLITE | - |
dc.subject.keywordPlus | CLINICAL-EFFICACY | - |
dc.subject.keywordAuthor | Calcium channel blocker | - |
dc.subject.keywordAuthor | Cilostazol | - |
dc.subject.keywordAuthor | Clopidogrel | - |
dc.subject.keywordAuthor | Platelet function test | - |
dc.subject.keywordAuthor | Thrombosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.